Total submissions: 3
| Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
|---|---|---|---|---|---|---|---|---|
| Labcorp Genetics |
RCV001921571 | SCV002203402 | uncertain significance | Bardet-Biedl syndrome | 2022-04-10 | criteria provided, single submitter | clinical testing | This sequence change replaces arginine, which is basic and polar, with glutamine, which is neutral and polar, at codon 165 of the TRIM32 protein (p.Arg165Gln). This variant is present in population databases (rs761591526, gnomAD 0.006%). This variant has not been reported in the literature in individuals affected with TRIM32-related conditions. Algorithms developed to predict the effect of missense changes on protein structure and function output the following: SIFT: "Tolerated"; PolyPhen-2: "Benign"; Align-GVGD: "Class C0". The glutamine amino acid residue is found in multiple mammalian species, which suggests that this missense change does not adversely affect protein function. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. |
| Fulgent Genetics, |
RCV002491932 | SCV002790839 | uncertain significance | Sarcotubular myopathy; Bardet-Biedl syndrome 11 | 2022-02-17 | criteria provided, single submitter | clinical testing | |
| Prevention |
RCV004749788 | SCV005365959 | uncertain significance | TRIM32-related disorder | 2024-08-20 | no assertion criteria provided | clinical testing | The TRIM32 c.494G>A variant is predicted to result in the amino acid substitution p.Arg165Gln. To our knowledge, this variant has not been reported in the literature. This variant is reported in 0.0087% of alleles in individuals of Latino descent in gnomAD. At this time, the clinical significance of this variant is uncertain due to the absence of conclusive functional and genetic evidence. |